QUREN Stock Chart & Stats
$799.00
$0.00(0.00%)
At close: 4:00 PM EDT
$799.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$265.00 - $1,087.92
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
$52.40B
Enterprise Value$2.79K
Total Cash (Recent Filing)$810.34M
Total Debt (Recent Filing)$62.83M
Price to Earnings (P/E)―
Beta-0.90
Next Earnings
Nov 10, 2026EPS Estimate
-15.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding69,366,410
10 Day Avg. Volume31
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,137.34Price Target Upside42.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-66.48
Revenue Forecast (FY)$380.24M
Bulls Say, Bears Say
Bulls Say
AMT-130 Regulatory ProgressSubmitting in both the United States and United Kingdom materially advances AMT-130 toward potential commercialization for Huntington’s disease. The therapy’s accelerated-approval pathway and priority-review request could improve regulatory access, while successful execution would establish uniQure in central-nervous-system gene therapy.
Extended Funding RunwayA projected operating runway into 2030 gives uniQure time to fund confirmatory studies, advance multiple programs and prepare for potential commercialization without immediate dependence on additional financing. This financial flexibility supports sustained investment through important clinical and regulatory milestones.
Multi-program Gene Therapy PipelineEarly AMT-260 results provide a second clinical opportunity beyond Huntington’s disease and suggest potential expansion into refractory epilepsy. Although preliminary, the seizure reductions and absence of related serious adverse events support continued development of uniQure’s AAV-based platform and pipeline diversification.
Bears Say
Persistent Operating LossesThe company’s current revenue base remains far too small to cover its operating structure, producing exceptionally deep losses despite a relatively high gross margin. Until a product generates meaningful recurring revenue, profitability depends on pipeline success, licensing activity and continued access to external capital.
Heavy Cash Burn And Lumpy RevenuePersistent negative operating and free cash flow means uniQure is consuming capital while its revenue stream remains dependent on irregular license and milestone payments. This reduces earnings visibility and makes future financial performance sensitive to partner execution, development progress and regulatory outcomes.
AMT-191 Dose-limiting ToxicityThe AMT-191 dosing pause interrupts development in Fabry disease and creates uncertainty around the program’s viable dose range and clinical path. Although the liver-enzyme events resolved with immunosuppression, restarting higher doses requires an FDA-agreed monitoring plan and adds execution risk.
uniQure News
QUREN FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $265.00 and its highest was $1087.92 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $52.40B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 10, 2026 which is in 63 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -$20.603 earnings per share for the quarter, missing the consensus estimate of -$13.881 by -$6.721.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -15.59.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 69,366,410 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$20.603 in its last earnings report, missing expectations of -$13.881. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in MX:QUREN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,137.34 (42.35% Upside)
$1,137.34 (42.35% Upside)
Blogger Sentiment
Bullish
MX:QUREN Sentiment 75%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $16.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QUREN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.View all MX:QUREN earnings summariesQUREN Stock 12 Month Forecast
Average Price Target
$1,137.34
▲(42.35% Upside)